Greg D. Learn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Greg D. Learn has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Horst A. von Recum
Department of Biomedical Engineering, Case Western Reserve University, Cleveland, USA
11 shared publications - Erika L. Cyphert
Shu Chien-Gene Lay Department of Bioengineering, University of California, San Diego, CA
4 shared publications Derrick M. Knapik
Department of Orthopaedic Surgery University Hospitals of Cleveland Cleveland Ohio
2 shared publications- Dylan W. Marques
Department of Biomedical Engineering, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106, USA
2 shared publications Emerson J. Lai
Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, USA
2 shared publications- Emerson J. Lai
Case Western Reserve University
2 shared publications
Latest Publications
- Open Access
A PMMA bone cement composite that functions as a drug-refillable depot for localized, multi-window chemotherapeutic treatment of bone cancer
Standard chemotherapy for primary and secondary bone tumors typically involves systemic administration of chemotherapeutic drugs, such as doxorubicin (DOX). However, non-targeted delivery increases dose requirements, and results in off-target toxicity and suboptimal chemotherapeutic efficacy. When chemotherapy is ineffective, substantial resection of tissue and/or total amputation become necessary – a debilitating outcome for any patient. In this work, we developed a proof-of-concept, non-biodegradable, mechanically robust, and refillable composite system for chemotherapeutic (i.e. DOX) delivery comprised of poly(methyl methacrylate) (PMMA) bone cement and insoluble polymeric γ-cyclodextrin (γ-CD) microparticles. The porosity and compressive strength of DOX-filled PMMA composites were characterized. DOX filling capacity, elution kinetics, cytotoxicity against primary osteosarcoma and lung cancer cells, and refilling capacity of composites were evaluated. PMMA composites containing up to 15wt% γ-CD microparticles provided consistent, therapeutically-relevant release of DOX with ~100% of the initial DOX released after 100 days. Over the same period, only ~6% of DOX was liberated from PMMA with free DOX. Following prolonged curing, PMMA composites with up to 15wt% γ-CD surpassed compressive strength requirements outlined by international standards for acrylic bone cements. Compared to DOX-filled PMMA, DOX-filled PMMA/γ-CD composites provided long-term release with decreased burst effect, correlating to long-term cytotoxicity against cancer cells. Refillable properties demonstrated by the PMMA composite system may find utility for treating local recurrences, limiting chemoresistance, and altering drug combinations to provide customized treatment regimens. Overall, findings suggest that PMMA composites have the potential to serve as a platform for the delivery of combinatorial chemotherapeutics to treat bone tumors.
Open AccessA PMMA bone cement composite that functions as a drug-refillable depot for localized, multi-window chemotherapeutic treatment of bone cancer
Standard chemotherapy for primary and secondary bone tumors typically involves systemic administration of chemotherapeutic drugs, such as doxorubicin (DOX). However, non-targeted delivery increases dose requirements, and results in off-target toxicity and suboptimal chemotherapeutic efficacy. When chemotherapy is ineffective, substantial resection of tissue and/or total amputation become necessary – a debilitating outcome for any patient. In this work, we developed a proof-of-concept, non-biodegradable, mechanically robust, and refillable composite system for chemotherapeutic (i.e. DOX) delivery comprised of poly(methyl methacrylate) (PMMA) bone cement and insoluble polymeric γ-cyclodextrin (γ-CD) microparticles. The porosity and compressive strength of DOX-filled PMMA composites were characterized. DOX filling capacity, elution kinetics, cytotoxicity against primary osteosarcoma and lung cancer cells, and refilling capacity of composites were evaluated. PMMA composites containing up to 15wt% γ-CD microparticles provided consistent, therapeutically-relevant release of DOX with ~100% of the initial DOX released after 100 days. Over the same period, only ~6% of DOX was liberated from PMMA with free DOX. Following prolonged curing, PMMA composites with up to 15wt% γ-CD surpassed compressive strength requirements outlined by international standards for acrylic bone cements. Compared to DOX-filled PMMA, DOX-filled PMMA/γ-CD composites provided long-term release with decreased burst effect, correlating to long-term cytotoxicity against cancer cells. Refillable properties demonstrated by the PMMA composite system may find utility for treating local recurrences, limiting chemoresistance, and altering drug combinations to provide customized treatment regimens. Overall, findings suggest that PMMA composites have the potential to serve as a platform for the delivery of combinatorial chemotherapeutics to treat bone tumors.
- Open Access
- 26 January 2021
- Published by MDPI AG in Journal of Functional Biomaterials
- Vol. 12 (1) , 8
Poly(methyl methacrylate) Bone Cement Composite Can Be Refilled with Antibiotics after Implantation in Femur or Soft Tissue
While periprosthetic joint infections (PJIs) result in a small percentage of patients following arthroplasties, they are challenging to treat if they spread into bone and soft tissue. Treatment involves delivering antibiotics using poly(methyl methacrylate) (PMMA) bone cement. However, antibiotic release is insufficient for prolonged infections. Previous work demonstrated efficacy of incorporating insoluble cyclodextrin (CD) microparticles into PMMA to improve antibiotic release and allow for post-implantation drug refilling to occur in a tissue-mimicking model. To simulate how antibiotic refilling may be possible in more physiologically relevant models, this work investigated development of bone and muscle refilling models. The bone refilling model involved embedding PMMA-CD into rabbit femur and administering antibiotic via intraosseous infusion. Muscle tissue refilling model involved implanting PMMA-CD beads in bovine muscle tissue and administering antibiotic via tissue injection. Duration of antimicrobial activity of refilled PMMA-CD was evaluated. PMMA-CD composite in bone and muscle tissue models was capable of being refilled with antibiotics and resulted in prolonged antimicrobial activity. PMMA-CD provided sustained and on-demand antimicrobial activity without removal of implant if infection develops. Intraosseous infusion appeared to be a viable technique to enable refilling of PMMA-CD after implantation in bone, reporting for the first time the ability to refill PMMA in bone.
- 26 January 2021
- Published by MDPI AG in Journal of Functional Biomaterials
- Vol. 12 (1) , 8
Open AccessPoly(methyl methacrylate) Bone Cement Composite Can Be Refilled with Antibiotics after Implantation in Femur or Soft Tissue
While periprosthetic joint infections (PJIs) result in a small percentage of patients following arthroplasties, they are challenging to treat if they spread into bone and soft tissue. Treatment involves delivering antibiotics using poly(methyl methacrylate) (PMMA) bone cement. However, antibiotic release is insufficient for prolonged infections. Previous work demonstrated efficacy of incorporating insoluble cyclodextrin (CD) microparticles into PMMA to improve antibiotic release and allow for post-implantation drug refilling to occur in a tissue-mimicking model. To simulate how antibiotic refilling may be possible in more physiologically relevant models, this work investigated development of bone and muscle refilling models. The bone refilling model involved embedding PMMA-CD into rabbit femur and administering antibiotic via intraosseous infusion. Muscle tissue refilling model involved implanting PMMA-CD beads in bovine muscle tissue and administering antibiotic via tissue injection. Duration of antimicrobial activity of refilled PMMA-CD was evaluated. PMMA-CD composite in bone and muscle tissue models was capable of being refilled with antibiotics and resulted in prolonged antimicrobial activity. PMMA-CD provided sustained and on-demand antimicrobial activity without removal of implant if infection develops. Intraosseous infusion appeared to be a viable technique to enable refilling of PMMA-CD after implantation in bone, reporting for the first time the ability to refill PMMA in bone.
- 1 January 2021
- Published by Elsevier in Journal of the Mechanical Behavior of Biomedical Materials
- Vol. 113, 104126
Nonthermal plasma treatment of polymers modulates biological fouling but can cause material embrittlement
- 1 January 2021
- Published by Elsevier in Journal of the Mechanical Behavior of Biomedical Materials
- Vol. 113, 104126
Nonthermal plasma treatment of polymers modulates biological fouling but can cause material embrittlement
- Open Access
Nonthermal Plasma Treatment Improves Uniformity and Adherence of Cyclodextrin-Based Coatings on Hydrophobic Polymer Substrates
Low surface energy substrates, which include many plastics and polymers, present challenges toward achieving uniform, adherent coatings, thus limiting intended coating function. These inert materials are common in various applications due to favorable bulk, despite suboptimal surface, properties. The ability to functionally coat low surface energy substrates holds broad value for uses across medicine and industry. Cyclodextrin-based materials represent an emerging, widely useful class of coatings, which have previously been explored for numerous purposes involving sustained release, enhanced sorption, and reversible reuse thereof. In this study, substrate exposure to nonthermal plasma was explored as a novel means to improve uniformity and adherence of cyclodextrin-based polyurethane coatings upon unreceptive polypropylene substrates. Plasma effects on substrates were investigated using contact angle goniometry and X-ray photoelectron spectroscopy (XPS). Plasma impact on coating uniformity was assessed through visualization directly and microscopically. Plasma effects on coating adhesion and bonding were studied with mechanical lap-shear testing and XPS, respectively. Substrate surface wettability and oxygen content increased with plasma exposure, and these modifications were associated with improved coating uniformity, adhesion, and interfacial covalent bonding. Findings demonstrate utility of, and elucidate mechanisms behind, plasma-based surface activation for improving coating uniformity, adherence, and performance on inert polymeric substrates.
Open AccessNonthermal Plasma Treatment Improves Uniformity and Adherence of Cyclodextrin-Based Coatings on Hydrophobic Polymer Substrates
Low surface energy substrates, which include many plastics and polymers, present challenges toward achieving uniform, adherent coatings, thus limiting intended coating function. These inert materials are common in various applications due to favorable bulk, despite suboptimal surface, properties. The ability to functionally coat low surface energy substrates holds broad value for uses across medicine and industry. Cyclodextrin-based materials represent an emerging, widely useful class of coatings, which have previously been explored for numerous purposes involving sustained release, enhanced sorption, and reversible reuse thereof. In this study, substrate exposure to nonthermal plasma was explored as a novel means to improve uniformity and adherence of cyclodextrin-based polyurethane coatings upon unreceptive polypropylene substrates. Plasma effects on substrates were investigated using contact angle goniometry and X-ray photoelectron spectroscopy (XPS). Plasma impact on coating uniformity was assessed through visualization directly and microscopically. Plasma effects on coating adhesion and bonding were studied with mechanical lap-shear testing and XPS, respectively. Substrate surface wettability and oxygen content increased with plasma exposure, and these modifications were associated with improved coating uniformity, adhesion, and interfacial covalent bonding. Findings demonstrate utility of, and elucidate mechanisms behind, plasma-based surface activation for improving coating uniformity, adherence, and performance on inert polymeric substrates.
- Open Access
- 17 January 2020
- Published by Cold Spring Harbor Laboratory in bioRxiv
Cyclodextrin polymer coatings resist protein fouling, mammalian cell adhesion, and bacterial attachment
Undesired attachment of proteins, cells/bacteria, and organisms on material surfaces is problematic in industrial and health care settings. In this study, polymer coatings are synthesized from subunits of cyclodextrin, an additive/excipient found in food/pharmaceutical formulations. These unique polymers, which have been applied mainly towards sustained drug delivery applications, are evaluated in this study for their ability to mitigate non-specific protein adsorption, mammalian cell (NIH/3T3) adhesion, and bacterial cell (Staphylococcus aureus, Escherichia coli) attachment. Effects of cyclodextrin polymer composition, particularly incorporation of nonpolar crosslinks, on material properties and passive anti-biofouling performance are investigated. Results suggest that lightly-crosslinked cyclodextrin polymers possess excellent passive resistance to protein, cell, and bacterial attachment, likely due to the hydrophilic and electrically neutral surface properties of these coatings. At the same time, anti-biofouling performance decreased with increasing crosslink ratios, possibly a reflection of decreased polymer mobility, increased rigidity, and increased hydrophobic character. Cyclodextrin-based materials may be broadly useful as coatings in industrial or medical applications where biofouling-resistant and/or drug-delivering surfaces are required.
- 17 January 2020
- Published by Cold Spring Harbor Laboratory in bioRxiv
Open AccessCyclodextrin polymer coatings resist protein fouling, mammalian cell adhesion, and bacterial attachment
Undesired attachment of proteins, cells/bacteria, and organisms on material surfaces is problematic in industrial and health care settings. In this study, polymer coatings are synthesized from subunits of cyclodextrin, an additive/excipient found in food/pharmaceutical formulations. These unique polymers, which have been applied mainly towards sustained drug delivery applications, are evaluated in this study for their ability to mitigate non-specific protein adsorption, mammalian cell (NIH/3T3) adhesion, and bacterial cell (Staphylococcus aureus, Escherichia coli) attachment. Effects of cyclodextrin polymer composition, particularly incorporation of nonpolar crosslinks, on material properties and passive anti-biofouling performance are investigated. Results suggest that lightly-crosslinked cyclodextrin polymers possess excellent passive resistance to protein, cell, and bacterial attachment, likely due to the hydrophilic and electrically neutral surface properties of these coatings. At the same time, anti-biofouling performance decreased with increasing crosslink ratios, possibly a reflection of decreased polymer mobility, increased rigidity, and increased hydrophobic character. Cyclodextrin-based materials may be broadly useful as coatings in industrial or medical applications where biofouling-resistant and/or drug-delivering surfaces are required.
- 26 December 2019
- Published by American Chemical Society (ACS) in Biomacromolecules
- Vol. 21 (2) , 854-866
Combination Antibiotic Delivery in PMMA Provides Sustained Broad-Spectrum Antimicrobial Activity and Allows for Postimplantation Refilling
Antibiotics are commonly added to poly(methyl methacrylate) (PMMA) by surgeons to locally treat infections such as in bone cement for joint replacement surgeries, but also as implantable antimicrobial "beads". However, this strategy is of limited value in high risk patients where infections can be recurrent or chronic and otherwise hard to treat. Also when only one drug is incorporated and applied toward poly-microbial infections (multiple bacterial species), there is a high risk that bacteria can develop antibiotic resistance. To combat these limitations, we developed a combination-antibiotic PMMA composite system comprised of rifampicin-filled β-cyclodextrin (β-CD) microparticles added into PMMA filled with a second drug. Different formulations were evaluated through Zone-of-Inhibition, drug activity, antibiotic release and re-filling, as well as mechanical studies. Our combination-antibiotic PMMA composite system achieved up to an eight-fold increase in duration of antimicrobial activity in comparison to clinically used antibiotic-filled PMMA. Inclusion of CD microparticles also allowed for refilling of additional antibiotics after simulated implantation, resulting in additional windows of therapeutic efficacy. Mechanical testing showed that our tested formulations did have a small, but significant decrease in mechanical properties when compared to unmodified controls. While further studies are needed to determine whether the tested formulations are still suitable for load-bearing applications (e.g. bone cement), our composites are certainly amenable for a variety of non-load bearing applications (e.g. antimicrobial "beads" and temporary spacer in two-stage arthroscopic revisions).
- 26 December 2019
- Published by American Chemical Society (ACS) in Biomacromolecules
- Vol. 21 (2) , 854-866
Combination Antibiotic Delivery in PMMA Provides Sustained Broad-Spectrum Antimicrobial Activity and Allows for Postimplantation Refilling
Antibiotics are commonly added to poly(methyl methacrylate) (PMMA) by surgeons to locally treat infections such as in bone cement for joint replacement surgeries, but also as implantable antimicrobial "beads". However, this strategy is of limited value in high risk patients where infections can be recurrent or chronic and otherwise hard to treat. Also when only one drug is incorporated and applied toward poly-microbial infections (multiple bacterial species), there is a high risk that bacteria can develop antibiotic resistance. To combat these limitations, we developed a combination-antibiotic PMMA composite system comprised of rifampicin-filled β-cyclodextrin (β-CD) microparticles added into PMMA filled with a second drug. Different formulations were evaluated through Zone-of-Inhibition, drug activity, antibiotic release and re-filling, as well as mechanical studies. Our combination-antibiotic PMMA composite system achieved up to an eight-fold increase in duration of antimicrobial activity in comparison to clinically used antibiotic-filled PMMA. Inclusion of CD microparticles also allowed for refilling of additional antibiotics after simulated implantation, resulting in additional windows of therapeutic efficacy. Mechanical testing showed that our tested formulations did have a small, but significant decrease in mechanical properties when compared to unmodified controls. While further studies are needed to determine whether the tested formulations are still suitable for load-bearing applications (e.g. bone cement), our composites are certainly amenable for a variety of non-load bearing applications (e.g. antimicrobial "beads" and temporary spacer in two-stage arthroscopic revisions).
- Open Access
Using nonthermal plasma treatment to improve quality and durability of hydrophilic coatings on hydrophobic polymer surfaces
Low surface energy substrates, which include many polymers in medicine/industry, present challenges toward achieving uniform, adherent, durable coatings, thus limiting intended coating function. Examples include hydrophobic polymers such as polypropylene, polyethylene, polytetrafluoroethylene, and polydimethylsiloxane. These inert materials are used in various biomedical implants due to favorable bulk properties despite perhaps unfavorable surface properties. The capability to coat such materials holds great value as the surface heavily influences biological response and implant function in vivo . Likewise, paint/ink coatings are often necessary on these same plastics, as their final appearance can be critical for automotive, packaging, and consumer products. Substrate exposure to nonthermal plasma was explored here as a means to improve quality of coatings, specifically cyclodextrin-based polyurethanes previously explored for biomedical applications such as controlled drug delivery and anti-biofouling, upon otherwise incompatible polypropylene substrates. Plasma treatment was found to increase wettability and oxygen content on substrate surfaces. These plasma-induced surface alterations were associated with enhanced coating uniformity, and improved coating/substrate adherence – determined to derive partly from interfacial covalent bond formation. Findings demonstrate the utility of plasma-based surface activation as a strategy to improve coating quality on polymeric substrates, and reveal insights regarding mechanisms by which plasma improves polymer coating adherence.
Open AccessUsing nonthermal plasma treatment to improve quality and durability of hydrophilic coatings on hydrophobic polymer surfaces
Low surface energy substrates, which include many polymers in medicine/industry, present challenges toward achieving uniform, adherent, durable coatings, thus limiting intended coating function. Examples include hydrophobic polymers such as polypropylene, polyethylene, polytetrafluoroethylene, and polydimethylsiloxane. These inert materials are used in various biomedical implants due to favorable bulk properties despite perhaps unfavorable surface properties. The capability to coat such materials holds great value as the surface heavily influences biological response and implant function in vivo . Likewise, paint/ink coatings are often necessary on these same plastics, as their final appearance can be critical for automotive, packaging, and consumer products. Substrate exposure to nonthermal plasma was explored here as a means to improve quality of coatings, specifically cyclodextrin-based polyurethanes previously explored for biomedical applications such as controlled drug delivery and anti-biofouling, upon otherwise incompatible polypropylene substrates. Plasma treatment was found to increase wettability and oxygen content on substrate surfaces. These plasma-induced surface alterations were associated with enhanced coating uniformity, and improved coating/substrate adherence – determined to derive partly from interfacial covalent bond formation. Findings demonstrate the utility of plasma-based surface activation as a strategy to improve coating quality on polymeric substrates, and reveal insights regarding mechanisms by which plasma improves polymer coating adherence.
- Open Access
Nonthermal plasma treatment of polymers modulates biological fouling but can cause material embrittlement
Plasma-based treatment is a prevalent strategy to alter biological response and enhance biomaterial coating quality at the surfaces of biomedical devices and implants, especially polymeric materials. Plasma, an ionized gas, is often thought to have negligible effects on the bulk properties of prosthetic substrates given that it alters the surface chemistry on only the outermost few nanometers of material. However, no studies to date have systematically explored the effects of plasma exposure on both the surface and bulk properties of a biomaterial. This work examines the time-dependent effects of a nonthermal plasma on the surface and bulk properties of polymeric implants, specifically polypropylene surgical meshes and sutures. Findings suggest that plasma exposure improved resistance to fibrinogen adsorption and Escherichia coli attachment, and promoted mammalian fibroblast attachment, although increased duration of exposure resulted in a state of diminishing returns. At the same time, it was observed that plasma exposure can be detrimental to the material properties of individual filaments (i.e. sutures), as well as the structural characteristics of knitted meshes, with longer exposures resulting in further embrittlement and larger changes in anisotropic qualities. Though there are few guidelines regarding appropriate mechanical properties of surgical textiles, the results from this investigation imply that there are ultimate exposure limits for plasma-based treatments of polymeric implant materials when structural properties must be preserved, and that the effects of a plasma on a given biomaterial should be examined carefully before translation to a clinical scenario.
Open AccessNonthermal plasma treatment of polymers modulates biological fouling but can cause material embrittlement
Plasma-based treatment is a prevalent strategy to alter biological response and enhance biomaterial coating quality at the surfaces of biomedical devices and implants, especially polymeric materials. Plasma, an ionized gas, is often thought to have negligible effects on the bulk properties of prosthetic substrates given that it alters the surface chemistry on only the outermost few nanometers of material. However, no studies to date have systematically explored the effects of plasma exposure on both the surface and bulk properties of a biomaterial. This work examines the time-dependent effects of a nonthermal plasma on the surface and bulk properties of polymeric implants, specifically polypropylene surgical meshes and sutures. Findings suggest that plasma exposure improved resistance to fibrinogen adsorption and Escherichia coli attachment, and promoted mammalian fibroblast attachment, although increased duration of exposure resulted in a state of diminishing returns. At the same time, it was observed that plasma exposure can be detrimental to the material properties of individual filaments (i.e. sutures), as well as the structural characteristics of knitted meshes, with longer exposures resulting in further embrittlement and larger changes in anisotropic qualities. Though there are few guidelines regarding appropriate mechanical properties of surgical textiles, the results from this investigation imply that there are ultimate exposure limits for plasma-based treatments of polymeric implant materials when structural properties must be preserved, and that the effects of a plasma on a given biomaterial should be examined carefully before translation to a clinical scenario.
- Open Access
- 6 November 2019
- Published by Cold Spring Harbor Laboratory in bioRxiv
- p. 832402
Combination antibiotic PMMA composites provide sustained broad-spectrum antimicrobial activity and allow for post-implantation refilling
Antibiotics are commonly added to poly(methyl methacrylate) (PMMA) by surgeons to locally treat infections such as in bone cement for joint replacement surgeries, but also as implantable antimicrobial “beads”. However, this strategy is of limited value in high risk patients where infections can be recurrent or chronic and otherwise hard to treat. Also when only one drug is incorporated and applied toward poly-microbial infections (multiple bacterial species), there is a high risk that bacteria can develop antibiotic resistance. To combat these limitations, we developed a combination-antibiotic PMMA composite system comprised of rifampicin-filled β-cyclodextrin (β-CD) microparticles added into PMMA filled with a second drug. Different formulations were evaluated through Zone-of-Inhibition, drug activity, antibiotic release and re-filling, as well as mechanical studies. Our combination-antibiotic PMMA composite system achieved up to an eight-fold increase in duration of antimicrobial activity in comparison to clinically used antibiotic-filled PMMA. Inclusion of CD microparticles also allowed for refilling of additional antibiotics after simulated implantation, resulting in additional windows of therapeutic efficacy. Mechanical testing showed that our tested formulations did have a small, but significant decrease in mechanical properties when compared to unmodified controls. While further studies are needed to determine whether the tested formulations are still suitable for load-bearing applications (e.g. bone cement), our composites are certainly amenable for a variety of non-load bearing applications (e.g. antimicrobial “beads” and temporary spacer in two-stage arthroscopic revisions).
- 6 November 2019
- Published by Cold Spring Harbor Laboratory in bioRxiv
- p. 832402
Open AccessCombination antibiotic PMMA composites provide sustained broad-spectrum antimicrobial activity and allow for post-implantation refilling
Antibiotics are commonly added to poly(methyl methacrylate) (PMMA) by surgeons to locally treat infections such as in bone cement for joint replacement surgeries, but also as implantable antimicrobial “beads”. However, this strategy is of limited value in high risk patients where infections can be recurrent or chronic and otherwise hard to treat. Also when only one drug is incorporated and applied toward poly-microbial infections (multiple bacterial species), there is a high risk that bacteria can develop antibiotic resistance. To combat these limitations, we developed a combination-antibiotic PMMA composite system comprised of rifampicin-filled β-cyclodextrin (β-CD) microparticles added into PMMA filled with a second drug. Different formulations were evaluated through Zone-of-Inhibition, drug activity, antibiotic release and re-filling, as well as mechanical studies. Our combination-antibiotic PMMA composite system achieved up to an eight-fold increase in duration of antimicrobial activity in comparison to clinically used antibiotic-filled PMMA. Inclusion of CD microparticles also allowed for refilling of additional antibiotics after simulated implantation, resulting in additional windows of therapeutic efficacy. Mechanical testing showed that our tested formulations did have a small, but significant decrease in mechanical properties when compared to unmodified controls. While further studies are needed to determine whether the tested formulations are still suitable for load-bearing applications (e.g. bone cement), our composites are certainly amenable for a variety of non-load bearing applications (e.g. antimicrobial “beads” and temporary spacer in two-stage arthroscopic revisions).
- 16 February 2019
- Published by Wiley in Journal of Biomedical Materials Research Part A
- Vol. 107 (7) , 1434-1442
Use of affinity allows anti‐inflammatory and anti‐microbial dual release that matches suture wound resolution
Surgical sutures are vulnerable to bacterial infections and biofilm formation. At the suture site, pain and undesirable, excess inflammation are additionally detrimental to wound healing. The development of a polymerized cyclodextrin (pCD) coated surgical suture introduces the capability to locally deliver both anti‐inflammatory and anti‐microbial drugs throughout the phases of acute and chronic healing. Local delivery allows for the improvement of wound healing while reducing related systemic side effects and drug resistance. Through testing, it has been shown that the fabrication of our pCD coating minimally affects the suture's mechanical properties. In vitro studies show measurable and consistent drug delivery for nearly 5 weeks. The therapeutic level of this delivery is sufficient to show inhibition of bacterial growth for 4 weeks, and free‐radical scavenging (an in vitro anti‐inflammatory activity approximation) for 2 weeks. With this pCD coating technique, we maintain clinical performance standards while also introducing a long‐term dual delivery system relevant to the wound healing timeframe. © 2019 Wiley Periodicals, Inc. J Biomed Mater Res Part A, 2019.
- 16 February 2019
- Published by Wiley in Journal of Biomedical Materials Research Part A
- Vol. 107 (7) , 1434-1442
Use of affinity allows anti‐inflammatory and anti‐microbial dual release that matches suture wound resolution
Surgical sutures are vulnerable to bacterial infections and biofilm formation. At the suture site, pain and undesirable, excess inflammation are additionally detrimental to wound healing. The development of a polymerized cyclodextrin (pCD) coated surgical suture introduces the capability to locally deliver both anti‐inflammatory and anti‐microbial drugs throughout the phases of acute and chronic healing. Local delivery allows for the improvement of wound healing while reducing related systemic side effects and drug resistance. Through testing, it has been shown that the fabrication of our pCD coating minimally affects the suture's mechanical properties. In vitro studies show measurable and consistent drug delivery for nearly 5 weeks. The therapeutic level of this delivery is sufficient to show inhibition of bacterial growth for 4 weeks, and free‐radical scavenging (an in vitro anti‐inflammatory activity approximation) for 2 weeks. With this pCD coating technique, we maintain clinical performance standards while also introducing a long‐term dual delivery system relevant to the wound healing timeframe. © 2019 Wiley Periodicals, Inc. J Biomed Mater Res Part A, 2019.